Corresponding Author: Richard B. Lipton, MD, Montefiore Headache Center, Albert Einstein College of Medicine, 1225 Morris Park Ave, Van Etten Bldg, Room 3c12c, Bronx, NY 10461 (richard.lipton@einstein.yu.edu).
Accepted for Publication: September 23, 2019.
Correction: This article was corrected on April 7, 2020, to correct an imprecise statement in the Discussion section and fix a typographical error in Figure 2.
Author Contributions: Dr Lipton had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Lipton, Lu, Finnegan, Szegedi, Trugman.
Acquisition, analysis, or interpretation of data: Lipton, Dodick, Ailani, Lu, Finnegan, Szegedi, Trugman.
Drafting of the manuscript: Lipton, Ailani, Szegedi, Trugman.
Critical revision of the manuscript for important intellectual content: Lipton, Dodick, Ailani, Lu, Finnegan, Szegedi, Trugman.
Statistical analysis: Lu.
Administrative, technical, or material support: Finnegan, Trugman.
Supervision: Ailani, Szegedi, Trugman.
Conflict of Interest Disclosures: Dr Lipton reports that he serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache; has received research support from the National Institutes of Health (NIH); receives support from the Migraine Research Foundation and the National Headache Foundation; has reviewed for the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS); serves as consultant, advisory board member, or has received honoraria from Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Novartis, Teva, and Vedanta; receives royalties from Wolff’s Headache and Informa; holds stock options in eNeura Therapeutics and Biohaven. Dr Dodick reports receiving personal fees from Amgen, Autonomic Technologies, Axsome, Aural Analytics, Allergan, Alder, Biohaven, Charleston Laboratories, Dr Reddy's Laboratories/Promius, Electrocore LLC, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Sun Pharma (India), Theranica, Teva, Vedanta, WL Gore, Zosano, ZP Opco, Foresite Capital, Oppenheimer, Upjohn (Division of Pfizer), Pieris, Revance, Equinox, Salvia, and Amzak Health; has received CME fees or royalty payments from Healthlogix, Medicom, Medlogix, Mednet, Miller Medical, PeerView, WebMD/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket, Global Scientific Communications, UpToDate, Oxford University Press, Cambridge University Press, and Wolters Kluwer; has stock options for Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, GBS/Nocira, Matterhorn/Ontologics, and King-Devick Technologies; serves as a consultant without fee for Aural Analytics, Healint, Second Opinion/Mobile Health, and Epien; sits on the board of directors for Epien, Matterhorn/Ontologics, and King-Devick Technologies; has a patent (17189376.1-1466) for a botulinum toxin dosage regimen for chronic migraine prophylaxis, for which he receives no fee; receives research support from the American Migraine Foundation, Henry Jackson Foundation, Department of Defense, and Sperling Foundation; receives professional society fees or reimbursement for travel from the American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, International Headache Society, and Canadian Headache Society; and has a use agreement through employer, Myndshft, Neuroassessment Systems. Dr Ailani reports that she serves as a consultant for, speaks on behalf of, or both for Allergan, Amgen, Alder, Avanir, Biohaven, Electrocore, Eli Lilly, Promius, Impel, Satsuma, Aptus, Miller Medical Communications, and Alpha sites and has served on clinical trials for Allergan, the American Migraine Foundation, and Theranica; and is an editor for Current Pain and Headache Reports. Drs Lu, Finnegan, Szegedi, and Trugman are full-time employees and stockholders of Allergan plc.
Funding/Support: This trial was sponsored by Allergan plc, Dublin, Ireland. Medical writing and editorial support were provided by Lela Creutz, PhD, and Lisa Feder, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, New Jersey, and Amy Kuang, PhD, of Allergan plc and funded by Allergan plc.
Role of the Funder/Sponsor: The design and conduct of the study, as well as collection, management, analysis, and interpretation of the data, were undertaken by the sponsor in collaboration with the academic authors. Preparation, review, and approval of the manuscript were done by all authors, and by a professional medical writer and editor employed by the sponsor. All authors approved the final manuscript for submission. The sponsor did not have the right to veto publication or to control the decision regarding to which journal the paper was submitted.
Disclaimer: The opinions expressed in this article are those of the authors.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank the participants and investigators who participated in this study. We acknowledge Hassan Lakkis, PhD, for his contributions to the statistical analyses of the results of this study. Hassan Lakkis was an employee of Allergan plc at the time these analyses were conducted. His current affiliation is unknown.
1.GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
Lancet Neurol. 2017;16(11):877-897. doi:
10.1016/S1474-4422(17)30299-5
PubMedGoogle ScholarCrossref 2.GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
Lancet. 2017;390(10100):1211-1259. doi:
10.1016/S0140-6736(17)32154-2
PubMedGoogle ScholarCrossref 3.Headache Classification Committee of the International Headache Society. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.
Cephalalgia. 2018;38(1):1-211. doi:
10.1177/0333102417738202PubMedGoogle ScholarCrossref 5.Buse
DC , Murray
S , Dumas
PK ,
et al. Life with migraine, effect on relationships, career and finances, and overall health and well-being: results of the Chronic Migraine Epidemiology and Outcomes (CAMEO) study [abstract MTIS2008-009].
Cephalalgia. 2018;38(1)(suppl):9-10.
Google Scholar 7.American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice.
Headache. 2019;59(1):1-18.
PubMedGoogle Scholar 8.Lipton
RB , Buse
DC , Serrano
D , Holland
S , Reed
ML . Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Headache. 2013;53(8):1300-1311. doi:
10.1111/head.12154
PubMedGoogle ScholarCrossref 14.Croop
R , Goadsby
PJ , Stock
DA ,
et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Lancet. 2019;394(10200):737-745. doi:
10.1016/S0140-6736(19)31606-X
PubMedGoogle ScholarCrossref 17.Cady
RK , McAllister
PJ , Spierings
EL ,
et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Headache. 2015;55(1):88-100. doi:
10.1111/head.12472
PubMedGoogle ScholarCrossref 21.Ho
TW , Ferrari
MD , Dodick
DW ,
et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Lancet. 2008;372(9656):2115-2123. doi:
10.1016/S0140-6736(08)61626-8
PubMedGoogle ScholarCrossref 25.Marmura
MJ , Silberstein
SD , Schwedt
TJ . The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies.
Headache. 2015;55(1):3-20. doi:
10.1111/head.12499
PubMedGoogle ScholarCrossref 26.Lipton
RB , Reed
ML , Kurth
T , Fanning
KM , Buse
DC . Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) Study.
Headache. 2017;57(10):1507-1521. doi:
10.1111/head.13179
PubMedGoogle ScholarCrossref